Thomas Pangerl
Impact in
- Epidemiology top 10%
- Neuroendocrine Tumor Research Advances
- Neurology top 10%
- Neuroblastoma Research and Treatments
Papers in
- Epidemiology 10
- Neuroendocrine Tumor Research Advances 10
-
- Radiopharmaceutical Chemistry and Applications 4
- Monoclonal and Polyclonal Antibodies Research 4
- Co-authors
- Irene Virgolini (12 shared papers)M. Leimer (7 shared papers)Claudia Bischof (4 shared papers)P. Angelberger (5 shared papers)Markus Peck‐Radosavljevic (4 shared papers)Gerhard Hamilton (4 shared papers)Robert Dudczak (5 shared papers)Amir Kurtaran (6 shared papers)
In The Last Decade
Thomas Pangerl
15 papers receiving 434 citations
Peers
Comparison fields: 5 of 43
- Epidemiology 244
- Neurology 99
- Radiology, Nuclear Medicine and Imaging 136
- Oncology 161
- Endocrinology, Diabetes and Metabolism 41
Countries citing papers authored by Thomas Pangerl
This map shows the geographic impact of Thomas Pangerl's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas Pangerl with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas Pangerl more than expected).
Fields of papers citing papers by Thomas Pangerl
This network shows the impact of papers produced by Thomas Pangerl. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas Pangerl. The network helps show where Thomas Pangerl may publish in the future.
Co-authors
The 25 scholars most cited alongside Thomas Pangerl, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Somatostatin receptor subtype specificity and in vivo binding of a novel tumor tracer, 99mTc-P829. | 1998 | 95 |
| 2 | 2002 | 74 | |
| 3 | 1999 | 69 | |
| 4 | New trends in peptide receptor radioligands. | 2001 | 37 |
| 5 | 111In-DOTA-lanreotide scintigraphy in patients with tumors of the lung. | 2001 | 32 |
| 6 | 1997 | 29 | |
| 7 | Effects of chemotherapeutic agents on expression of somatostatin receptors in pancreatic tumor cells. | 2001 | 28 |
| 8 | New radiopharmaceuticals for receptor scintigraphy and radionuclide therapy. | 2000 | 18 |
| 9 | 2008 | 17 | |
| 10 | 2010 | 16 | |
| 11 | 1999 | 14 | |
| 12 | 1998 | 10 | |
| 13 | 1998 | 4 | |
| 14 | 1998 | 3 | |
| 15 | Spin hot spots in single-electron GaAs-based quantum dots | 2013 | 2 |
About Thomas Pangerl
Thomas Pangerl is a scholar working on Epidemiology, Radiology, Nuclear Medicine and Imaging, Oncology, Surgery and Molecular Biology, having authored 15 papers that have together received 448 indexed citations. Recurring topics across this work include Neuroendocrine Tumor Research Advances (10 papers), Lung Cancer Research Studies (5 papers), Radiopharmaceutical Chemistry and Applications (4 papers), Monoclonal and Polyclonal Antibodies Research (4 papers), Pancreatic and Hepatic Oncology Research (1 paper), Enhanced Recovery After Surgery (1 paper), Glycosylation and Glycoproteins Research (1 paper) and Gallbladder and Bile Duct Disorders (1 paper). The work is most often cited by research in Epidemiology (244 citations), Neurology (99 citations), Radiology, Nuclear Medicine and Imaging (136 citations), Oncology (161 citations) and Endocrinology, Diabetes and Metabolism (41 citations). Thomas Pangerl has collaborated with scholars based in Austria, Germany and Japan. Frequent co-authors include Irene Virgolini, M. Leimer, Claudia Bischof, P. Angelberger, Markus Peck‐Radosavljevic, Gerhard Hamilton, Robert Dudczak, Amir Kurtaran, Klaus Kaserer and Peter Smith‐Jones. Their work appears in journals such as JNCI Journal of the National Cancer Institute, BMC Systems Biology, The American Journal of Gastroenterology, European Journal of Clinical Investigation and Current Pharmaceutical Design.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.